Advertisement

Clinical Rheumatology

, Volume 37, Issue 9, pp 2391–2397 | Cite as

Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol

  • Alina Soare
  • Ana Maria GheorghiuEmail author
  • Victoria Aramă
  • Dragoș Bumbăcea
  • Rucsandra Dobrotă
  • Raida Oneaţă
  • Simona Pintilie
  • Mihaela Milicescu
  • Ioan Ancuţa
  • Andrei Martin
  • Mariana Sasu
  • Claudia Ciofu
  • Liviu Macovei
  • Victor Stoica
  • Mihai Bojincă
  • Carina Mihai
Original Article

Abstract

Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). This study aimed to assess the incidence of active TB and the efficacy of TB prevention measures used over the years, and to determine risk factors for developing TB, in a single-centre cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) receiving TNFi. Data of all patients in whom treatment with TNFi was initiated in our rheumatology clinic until December 1st 2014 have been retrospectively analysed. The cohort was divided into 3 groups per the mandatory LTBI screening method at baseline: tuberculin skin test (TST) with a positive threshold of either 10 mm (group TST1), or 5 mm (group TST2), and QuantiFERON®-TB Gold test (group QFT). The incidence of active TB was analysed for each group and compared to TB incidence data in general population. Five hundred fifty patients were included (305 RA, 42 PsA, 203 AS); 97 patients belonged to the TST1, 229 to the TST2 and 224 to the QFT group. The number of active TB cases/time of exposure to TNFi (person-years, PY) was 8/593.5, 9/1044.0 and 3/555.3, respectively, accounting for an incidence of 1348.0, 862.1 and 540.2 cases per 105 PY. Active TB cases occurring in the first year of TNFi treatment (early TB) per total TB cases were only 3/8, 1/9 and 1/3, respectively, too few to identify statistically significant differences between the 3 LTBI screening protocols. However, less TB cases per total observation time were registered in the QFT group, probably due to the reduced duration of exposure to TNFi. All cases of active TB were registered among patients receiving monoclonal antibodies TNFi agents. We have found no significant risk factors for developing active TB. In our cohort, TB occurring after 1 year of TNFi treatment exceeds ‘early TB’, suggesting the necessity of further TB prevention measures besides baseline screening for LTBI.

Keywords

Ankylosing spondylitis Biologics Inflammatory arthritis Psoriatic arthritis Rheumatoid arthritis Screening TNF inhibitors Tuberculosis 

Notes

Authors’ contribution

All authors participated in study design. MM, IA, AM, MS, CC, LM, MB, VS and CM recruited patients. AS, AMG, RD, RO and SP collected data. AS, AMG, DB and CM conducted the statistical analyses. VA and DB analysed TB cases and offered expert opinion in the area of TB. AS, AMG, DB and CM drafted the manuscript, which was critically reviewed, edited and approved for submission by all authors.

Compliance with ethical standards

All patients receiving TNFi in our centre gave written informed consent enabling the centre to use their de-identified medical data in research projects, and this study was approved by the local ethics committee.

Disclosure of interest

A. M. Gheorghiu: none declared. A. Soare: none declared. V. Aramă has received research support and/or honoraria and has/had consultancy relationship from Abbvie, MSD, BMS, Roche and Pfizer. D. Bumbăcea: none declared. R. Dobrotă: none declared. R. Oneață: none declared. S. Pintilie: none declared. M. Milicescu has received research support and/or honoraria from Abbvie, MSD and Pfizer. I. Ancuta has received research support and/or honoraria and has/had consultancy relationship from Abbvie, Pfizer, Roche, UCB and BMS. A. Martin has received research support and/or honoraria from Abbvie, MSD, Pfizer, Roche, UCB and BMS. M. Sasu has received research support and/or honoraria from Abbvie, MSD, Pfizer, Roche, UCB and BMS. C. Ciofu has received research support and/or honoraria from Abbvie and MSD. L. Macovei has received research support and/or honoraria from MSD, Pfizer and Roche. V. Stoica has received research support and/or honoraria from GSK, PSI Pharma Support, M&M CRE, Kendle International Inc. and Clintec International. M. Bojincă has served as a consultant for Abbvie, BMS, MSD, Pfizer, Roche, Sandoz and has received speaker fees from Abbvie, BMS, MSD, Pfizer, Roche, Gedeon Richter, Sandoz, UCB and Zentiva. C. Mihai has received research support and/or honoraria and has/had consultancy relationship from Abbvie, Abbott, BMS, MSD, Pfizer, Roche, Sandoz, Teva and UCB.

References

  1. 1.
    Swierkot J, Madej M (2011) The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors. Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego 30(178):283–288Google Scholar
  2. 2.
    Haugeberg G, Boyesen P, Helgetveit K, Proven A (2015) Clinical and radiographic outcomes in patients diagnosed with early rheumatoid arthritis in the first years of the biologic treatment era: a 10-year prospective observational study. J Rheumatol 42(12):2279–2287.  https://doi.org/10.3899/jrheum.150384 CrossRefPubMedGoogle Scholar
  3. 3.
    Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD005468.  https://doi.org/10.1002/14651858.CD005468.pub2 CrossRefGoogle Scholar
  4. 4.
    Mease PJ (2015) Biologic therapy for psoriatic arthritis. Rheum Dis Clin N Am 41(4):723–738.  https://doi.org/10.1016/j.rdc.2015.07.010 CrossRefGoogle Scholar
  5. 5.
    Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37–42.  https://doi.org/10.1136/annrheumdis-2011-200690 CrossRefPubMedGoogle Scholar
  6. 6.
    Winthrop KL (2012) Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin N Am 38(4):727–745.  https://doi.org/10.1016/j.rdc.2012.08.019 CrossRefGoogle Scholar
  7. 7.
    Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Dominguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C, TBNET (2014) Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190(10):1168–1176.  https://doi.org/10.1164/rccm.201405-0967OC CrossRefPubMedGoogle Scholar
  8. 8.
    Sester M, Bumbacea D, Duarte R, Lange C (2012) TB in the immunocompromised host. Eur Respir Soc Monogr 58:230–241.  https://doi.org/10.1183/1025448x.erm5812 CrossRefGoogle Scholar
  9. 9.
    Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW (2015) To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 73(3):420–428 e421.  https://doi.org/10.1016/j.jaad.2015.06.004 CrossRefPubMedGoogle Scholar
  10. 10.
    Nayak S, Acharjya B (2012) Mantoux test and its interpretation. Indian Dermatol Online J 3(1):2–6.  https://doi.org/10.4103/2229-5178.93479 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cojocaru C, Panescu M, Vasilescu C, Mihaescu T (2010) Comparative study using tuberculin from Cantacuzino institute versus Statens serum institute. Maedica 5(1):20–23PubMedPubMedCentralGoogle Scholar
  12. 12.
    Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement (2000) Am J Respir Crit Care Med 161(4 Pt 2):S221–247.  https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  13. 13.
    Bumbacea D, Lungu R, Pele I, Neagu A, Alexiu I, Ecomomescu MC, Bumbacea S, Diaconu CC (2011) New immunodiagnostic tests for latent and active tuberculosis. Rom J Lab Med 19(3/4):267–278Google Scholar
  14. 14.
    Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, Committee IE, Centers for Disease C, Prevention (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep 59(RR-5):1–25PubMedGoogle Scholar
  15. 15.
    Popescu GG, Spinu V, Chiotan DI (2014) Aspects of TB endemia in Romania and the response of the National Programme for Prevention, Surveillance and Control of Tuberculosis. Pneumologia 63(1):12–14 16-18PubMedGoogle Scholar
  16. 16.
    IBM Corp. Released (2011) IBM SPSS Statistics for Macintosch, Version 20.0. IBM Corp, ArmonkGoogle Scholar
  17. 17.
    Open Source Epidemiologic Statistics for Public Health application (http://openepi.com)
  18. 18.
    Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68(12):1863–1869.  https://doi.org/10.1136/ard.2008.102103 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sanchez-Moya AI, Dauden E (2011) Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol: JEADV 25(6):730–733.  https://doi.org/10.1111/j.1468-3083.2010.03836.x CrossRefPubMedGoogle Scholar
  20. 20.
    Paluch-Oles J, Magrys A, Koziol-Montewka M, Koszarny A, Majdan M (2013) Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-alpha agents. Arch Med Sci: AMS 9(1):112–117.  https://doi.org/10.5114/aoms.2013.33352 CrossRefPubMedGoogle Scholar
  21. 21.
    Saidenberg-Kermanac’h N, Semerano L, Naccache JM, Brauner M, Falgarone G, Dumont-Fischer D, Guillot X, Valeyre D, Boissier MC (2012) Screening for latent tuberculosis in anti-TNF-alpha candidate patients in a high tuberculosis incidence setting. Int J Tuberc Lung Dis 16(10):1307–1314.  https://doi.org/10.5588/ijtld.12.0111 CrossRefPubMedGoogle Scholar
  22. 22.
    Swaminath A, Bhadelia N, Wang YC (2013) Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis 19(11):2444–2449.  https://doi.org/10.1097/MIB.0b013e31829f008f CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ai JW, Zhang S, Ruan QL, YQ Y, Zhang BY, Liu QH, Zhang WH (2015) The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 42(12):2229–2237.  https://doi.org/10.3899/jrheum.150057 CrossRefPubMedGoogle Scholar
  24. 24.
    Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA (2016) Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res 68(8):1078–1088.  https://doi.org/10.1002/acr.22815 CrossRefGoogle Scholar
  25. 25.
    Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Consortium BSRBRCC, Symmons DP, Register BSRB (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522–528.  https://doi.org/10.1136/ard.2009.118935 CrossRefPubMedGoogle Scholar
  26. 26.
    Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A (2016) Characteristics predicting tuberculosis risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43(3):524–529.  https://doi.org/10.3899/jrheum.150177 CrossRefPubMedGoogle Scholar
  27. 27.
    Borekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G (2015) Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment. Respiration 90(3):191–198.  https://doi.org/10.1159/000434684 CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  • Alina Soare
    • 1
    • 2
  • Ana Maria Gheorghiu
    • 1
    • 2
    Email author
  • Victoria Aramă
    • 2
    • 3
  • Dragoș Bumbăcea
    • 2
    • 4
  • Rucsandra Dobrotă
    • 1
    • 2
  • Raida Oneaţă
    • 1
    • 2
  • Simona Pintilie
    • 1
    • 2
  • Mihaela Milicescu
    • 1
    • 2
  • Ioan Ancuţa
    • 1
    • 2
  • Andrei Martin
    • 1
    • 2
  • Mariana Sasu
    • 1
  • Claudia Ciofu
    • 1
    • 2
  • Liviu Macovei
    • 1
    • 2
  • Victor Stoica
    • 1
    • 2
  • Mihai Bojincă
    • 1
    • 2
  • Carina Mihai
    • 1
    • 2
  1. 1.Department of Internal Medicine and RheumatologyCantacuzino Clinical HospitalBucharestRomania
  2. 2.Carol Davila University of Medicine and PharmacyBucharestRomania
  3. 3.Infectious Diseases 3 DepartmentMatei Bals National Institute for Infectious DiseasesBucharestRomania
  4. 4.Department of PneumologyElias Emergency University HospitalBucharestRomania

Personalised recommendations